Going Global Is Not About Finding Distributors — It’s About Building a Growth System

The Direction Is Right — But the Approach Is Often Wrong

Over the past three years, the case for Chinese MedTech companies going international has become undeniable. Volume-based procurement pressure domestically, plateauing growth, and valuation corrections have collectively pointed toward one conclusion: overseas markets are the next frontier.

The underlying logic is sound. The capacity, pricing structures, and long-term payer dynamics of international markets can genuinely sustain the next decade of growth for Chinese MedTech firms.

The problem lies in execution. A large number of companies are entering overseas markets with nearly identical playbooks — attending the same handful of trade shows, working with the same pool of distributors, repurposing domestic product configurations, and competing on price against the same set of customers.

When every company uses the same moves to enter the same markets, the outcome is not growth — it is more intense price competition, replicated offshore.

The real issue is not the direction. It is that most companies treat internationalization as a set of short-term actions rather than a long-term system that needs to be deliberately built and continuously refined.

The “Low-Hanging Fruit” Myth Is Causing Costly Mistakes

A common narrative in early-stage international expansion circles is that overseas markets are full of low-hanging fruit — that simply showing up is enough to win business, that signing a distributor means entering a market, that obtaining a registration certificate means building share.

The reality is considerably more demanding. A registration process in a new emerging market may take 18 months. A seemingly active distributor may simultaneously carry five competing product lines. A stable-looking customer account may switch suppliers the moment a budget cycle changes. A market with attractive margins on paper may be eroded rapidly by currency volatility.

None of these are low-hanging fruit. They are outcomes that require systematic capability to capture reliably.

Many companies show solid momentum in their first two years — orders are coming in, the trajectory looks encouraging. But by year three or four, growth stalls. The distributor network has not matured, the product has not been iterated for local needs, and no organizational knowledge has been accumulated. This is not bad luck. It is the predictable consequence of never treating internationalization as a system from day one.

Avoiding one structural mistake is worth more than signing one additional customer. Companies that last are not the fastest starters — they are the ones that avoid systemic errors at each critical inflection point.

Why Most Internationalization Efforts Resemble Blind Men and an Elephant

When asked directly — what are you actually trying to build through your international expansion? — founders typically give answers that are each partially correct but collectively incomplete. Some say they want to enter Europe. Some say they need to find distributors. Some say the priority is Medica. Some say they need to establish a local entity. Some say registration is the first step.

Each answer reflects a real and legitimate concern. But none of them describes a complete system.

International expansion is a multi-dimensional engineering challenge. At minimum, it spans twelve functional domains: target market selection, regulatory access, market entry strategy, business model design, commercial team structure, international platform and brand presence, sales management, market management, project management, product management, data infrastructure, and customer relationship management.

The value of thinking across all twelve domains is not in memorizing a list — it is in forcing a company to ask:

• Which of these areas do we already have capability in?
• Where are our genuine blind spots?
• Which gaps are critical to address now, and which can be sequenced into the roadmap?

A company might be technically strong in product development but have almost no channel management discipline. It may be active at trade shows but have no structured customer follow-up process. It may have invested heavily in registrations but have no understanding of how end customers in those markets actually make purchasing decisions.

The most dangerous gap is not any single weak area — it is not knowing which areas are weak in the first place.

Systematic thinking shifts a company from reactive problem-solving to proactive path design.

International Expansion Is a CEO Mandate, Not a Department Task

A common organizational mistake is to assign international expansion to an international business unit or a single regional director and treat it as a department-level function.

This consistently underestimates the scope of what is actually involved. Internationalization requires decisions across product definition (should we develop market-specific configurations?), R&D prioritization (which features are being built for international customers?), regulatory sequencing (in what order do we pursue certifications?), manufacturing planning (how do export-oriented production lines fit into the overall schedule?), finance (foreign currency, repatriation, transfer pricing), HR (overseas hiring, expatriate management, cross-cultural team coordination), and IT infrastructure (does the CRM, CPQ, or ERP support multi-market operations?).

None of these questions can be decided unilaterally by an international sales team.

When the CEO delegates the entire internationalization agenda to a functional head without setting strategic direction, resource priorities, and cross-functional alignment, one of two things typically happens. Either the international team runs hard but cannot move internal stakeholders, and the function becomes a sales unit fighting alone. Or the international team generates a set of orders through pure sales effort, but those orders never compound into product capability, channel capability, or organizational capability — and the company’s international progress stays permanently at “we sell some product overseas.”

CEO involvement does not mean micromanagement. It means taking personal ownership of three things: strategic direction, resource allocation, and organizational alignment. No functional department can substitute for that.

The Core Characteristic of a Growth System: It Can Evolve Itself

A growth system is not a slide deck, a set of SOPs, a handbook, or a collection of KPIs. Its defining characteristic is that it can learn, improve, and adapt on its own — based on what is actually happening in the market.

A functioning international growth system has four specific capabilities:

It iterates based on market feedback. If a distributor is underperforming, the system can identify the root cause and adjust selection criteria. If a product positioning is off, the system can surface that signal from customer interactions and drive product iteration from the outside in.

It converts individual experience into organizational capability. When a salesperson leaves, their customer relationships, market knowledge, and competitive intelligence should not leave with them. When a market manager rotates, their judgment and methodology should be transferable to a successor.

It transfers proven capabilities across markets. A channel management framework that works in Europe should be adaptable to the Middle East. A KOL engagement mechanism developed in Latin America should be translatable to Southeast Asia.

It continuously optimizes resource allocation. Decisions about which markets to scale, which to maintain, and which to strategically exit should be driven by a structured data and evaluation framework — not by a founder’s intuition alone.

A one-time market action does not constitute a competitive advantage. A self-evolving growth system is the real moat.

Importantly, this system looks different in every company. Channel management for a surgical consumables business is fundamentally different from that of an imaging equipment company. Team-building for a 500-person company operates on a different design logic than for a 3,000-person organization. The value of a system framework is not standardization — it is that it can be calibrated to fit each company’s specific stage, product, and market context.

What Companies Actually Need to Keep Improving

Based on sustained engagement with Chinese MedTech companies across internationalization stages, four dimensions consistently separate companies that build durable international presence from those that plateau.

Business logic clarity. Why should your product win in this specific overseas market — on price, technology, or clinical differentiation? Is that logic consistent across markets? Does it hold up against customer scrutiny, competitive pressure, and time?

Strategic direction accuracy. Does your target market genuinely match your current product capability and resource level? Does your entry approach fit your company’s development stage? Is the pace you have set realistic?

Execution discipline. Even the best strategy produces nothing without follow-through. Are trade show leads being systematically converted? Are distributor performance reviews actually happening? Is clinical support being delivered to end customers as promised?

Team capability development. The skills that drove early wins — trade show prospecting, initial order acquisition — are not the same skills required at scale. Refined channel management, clinical KOL development, and cross-border project management require deliberate investment in team capability over time.

None of these improve through a single training session or a one-off consulting engagement. They require sustained attention within a long-term framework.

Five Questions Every Founder Should Be Able to Answer

Rather than a generic action checklist, these five questions are worth honest reflection for any founder currently navigating or preparing for international expansion:

1. Is our international expansion a structured effort with clear direction, sequenced priorities, and a defined roadmap — or a series of opportunity-driven, disconnected actions?
2. Across the twelve functional dimensions of international growth, which areas have we genuinely built capability in, and which remain blind spots?
3. Is our understanding of overseas markets grounded in direct feedback from customers, channel partners, and competitors — or does it rely primarily on trade show impressions, industry reports, and secondhand accounts?
4. Has our international strategy been designed with the CEO’s direct involvement, or has it been delegated entirely to a business unit?
5. Three years from now, will our international business have compounded into a self-sustaining growth system — or will it still be a collection of individual orders?

There are no universal correct answers. But the process of working through these questions honestly is precisely where the shift from reactive internationalization to systematic internationalization begins.